Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

Similar articles for PubMed (Select 22321026)

1.

Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

Wills T, Vega V.

Expert Opin Investig Drugs. 2012 Mar;21(3):395-401. doi: 10.1517/13543784.2012.658914. Epub 2012 Feb 10. Review.

PMID:
22321026
2.

Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.

White K, Kulkarni R, Miller MD.

J Antimicrob Chemother. 2015 Jun 24. pii: dkv149. [Epub ahead of print]

PMID:
26108607
3.
4.

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.

Despiégel N, Anger D, Martin M, Monga N, Cui Q, Rocchi A, Pulgar S, Gilchrist K, Refoios Camejo R.

Infect Dis Ther. 2015 Jun 23. [Epub ahead of print]

PMID:
26099626
5.

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

Calcagno A, D'Avolio A, Bonora S.

Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1167-76. doi: 10.1517/17425255.2015.1056732.

PMID:
26073580
6.

Formulation and pharmacology of long-acting cabotegravir.

Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S.

Curr Opin HIV AIDS. 2015 Jul;10(4):239-45. doi: 10.1097/COH.0000000000000168.

PMID:
26049948
8.

HIV integrase inhibitors: a new era in the treatment of HIV.

Blanco JL, Whitlock G, Milinkovic A, Moyle G.

Expert Opin Pharmacother. 2015 Jun;16(9):1313-24. doi: 10.1517/14656566.2015.1044436.

PMID:
26001181
9.

Will drug resistance against dolutegravir in initial therapy ever occur?

Wainberg MA, Han YS.

Front Pharmacol. 2015 Apr 29;6:90. doi: 10.3389/fphar.2015.00090. eCollection 2015. Review.

10.

First-in-class HIV drug enters phase 3 trials.

Azvolinsky A.

Nat Biotechnol. 2015 May 12;33(5):439. doi: 10.1038/nbt0515-439a. No abstract available.

PMID:
25965738
11.

Infectious disease: New HIV-1 prodrug shows promise in phase III trials.

Stone L.

Nat Rev Urol. 2015 Jun;12(6):301. doi: 10.1038/nrurol.2015.96. Epub 2015 May 5. No abstract available.

PMID:
25941789
12.

An unexpected interaction between warfarin and cobicistat-boosted elvitegravir.

Good BL, Gomes DC, Fulco PP.

AIDS. 2015 May 15;29(8):985-6. doi: 10.1097/QAD.0000000000000630. No abstract available.

PMID:
25909832
13.

[Position of dolutegravir in the treatment of HIV infection].

Martínez E, Gatell JM.

Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:31-3. doi: 10.1016/S0213-005X(15)30007-0. Spanish.

PMID:
25858610
14.

[Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].

Moreno S, Berenguer J.

Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:26-30. doi: 10.1016/S0213-005X(15)30006-9. Spanish.

PMID:
25858609
15.

[Efficacy of dolutegravir in treatment-naïve patients. The SPRING-1, SPRING-2, SINGLE and FLAMINGO trials].

Bernardino JI, Antela A.

Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:14-9. doi: 10.1016/S0213-005X(15)30004-5. Spanish.

PMID:
25858607
16.

[Safety profile of dolutegravir].

Rivero A, Domingo P.

Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:9-13. doi: 10.1016/S0213-005X(15)30003-3. Spanish.

PMID:
25858606
17.

Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Andreatta KN, Goodman DD, Miller MD, White KL.

Antimicrob Agents Chemother. 2015 Jun;59(6):3441-9. doi: 10.1128/AAC.00040-15. Epub 2015 Mar 30.

PMID:
25824231
18.

Stribild: a review of component characteristics and combination drug efficacy.

Murrell DE, Moorman JP, Harirforoosh S.

Eur Rev Med Pharmacol Sci. 2015;19(5):904-14.

19.

The role of dolutegravir in the management of HIV infection.

Miller MM, Liedtke MD, Lockhart SM, Rathbun RC.

Infect Drug Resist. 2015 Feb 19;8:19-29. doi: 10.2147/IDR.S58706. eCollection 2015. Review.

20.

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.

Massud I, Martin A, Dinh C, Mitchell J, Jenkins L, Heneine W, Pau CP, García-Lerma JG.

J Antimicrob Chemother. 2015 May;70(5):1473-81. doi: 10.1093/jac/dku556. Epub 2015 Jan 27.

PMID:
25630643
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk